Analysts See $-0.71 EPS for Regenxbio Inc. (RGNX)

February 12, 2018 - By Vivian Park

 Analysts See $ 0.71 EPS for Regenxbio Inc. (RGNX)

Analysts expect Regenxbio Inc. (NASDAQ:RGNX) to report $-0.71 EPS on March, 6.They anticipate $0.03 EPS change or 4.05 % from last quarter’s $-0.74 EPS. After having $-0.67 EPS previously, Regenxbio Inc.’s analysts see 5.97 % EPS growth. The stock increased 0.78% or $0.2 during the last trading session, reaching $25.7. About 276,438 shares traded. Regenxbio Inc. (NASDAQ:RGNX) has risen 51.43% since February 12, 2017 and is uptrending. It has outperformed by 34.73% the S&P500.

Regenxbio Inc. (NASDAQ:RGNX) Ratings Coverage

Among 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Regenxbio had 4 analyst reports since October 12, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, October 12 by Bank of America. The stock of Regenxbio Inc. (NASDAQ:RGNX) has “Overweight” rating given on Monday, October 12 by Piper Jaffray. The company was initiated on Tuesday, October 13 by Morgan Stanley. Chardan Capital Markets initiated Regenxbio Inc. (NASDAQ:RGNX) rating on Tuesday, October 20. Chardan Capital Markets has “Buy” rating and $33 target.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The company has market cap of $800.43 million. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. It currently has negative earnings. The company's lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.

More notable recent Regenxbio Inc. (NASDAQ:RGNX) news were published by: which released: “Form SC 13G/A REGENXBIO Inc. Filed by: BlackRock Inc.” on January 23, 2018, also with their article: “REGENXBIO to Participate in Upcoming Investor Conferences” published on February 07, 2018, published: “REGENXBIO Responds to Notification of a Superior Proposal Under Its Merger …” on October 02, 2017. More interesting news about Regenxbio Inc. (NASDAQ:RGNX) were released by: and their article: “REGENXBIO Announces Completion of Dosing of Third Cohort in Phase I Clinical …” published on February 08, 2018 as well as‘s news article titled: “REGENXBIO Enhances Gene Therapy Manufacturing Capabilities by Entering into …” with publication date: January 23, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: